<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;utm_medium=rss&amp;ff=20240919001300&amp;v=2.18.0.post9+e462414&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;utm_medium=rss&amp;ff=20240919001300&amp;v=2.18.0.post9+e462414&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Thu, 19 Sep 2024 04:13:01 +0000</lastbuilddate>
<pubDate>Wed, 18 Sep 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Importance of Prolonged QRS Duration in Detecting Complete Conduction Block</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39292498/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240919001300&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Sep 18. doi: 10.1001/jamacardio.2024.2963. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39292498/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240919001300&v=2.18.0.post9+e462414">39292498</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2963>10.1001/jamacardio.2024.2963</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39292498</guid>
<pubDate>Wed, 18 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Mahbod Rahimi</dc:creator>
<dc:creator>Vijay S Chauhan</dc:creator>
<dc:date>2024-09-18</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Importance of Prolonged QRS Duration in Detecting Complete Conduction Block</dc:title>
<dc:identifier>pmid:39292498</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2963</dc:identifier>
</item>
<item>
<title>Exploring the Link Between Genetic Predictors of Cardiovascular Disease and Psoriasis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39292496/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240919001300&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Findings of this mendelian randomization study indicate that genetic predictors of cardiovascular disease were associated with increased psoriasis risk with no reciprocal effect or association with other IMIDs. Elucidating mechanisms underpinning this association could lead to novel therapeutic approaches in both diseases.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Sep 18. doi: 10.1001/jamacardio.2024.2859. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: The epidemiological link between immune-mediated diseases (IMIDs) and cardiovascular disease has often been attributed to systemic inflammation. However, the direction of causality and the biological mechanisms linking cardiovascular disease with IMIDs are incompletely understood. Given the robust epidemiological association and the growing body of supportive mechanistic evidence, psoriasis is an exemplary IMID model for exploring this relationship.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To assess the bidirectional relationships between genetic predictors of psoriasis and the 2 major forms of cardiovascular disease, coronary artery disease (CAD) and stroke, and to evaluate the association between genetic predictors of cardiovascular disease with 9 other IMIDs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This was a genetic association study using mendelian randomization (MR), a powerful genetic tool to help distinguish causation from associations observed in epidemiological studies, to provide supportive evidence for causality between traits. The study conducted 2-sample MR analyses using summary-level data from large-scale genome-wide association meta-analysis studies (GWAS) for each trait. The analysis focused on individuals of European descent from GWAS meta-analyses, involving CAD, stroke, psoriasis, and 9 other IMIDs. Data were analyzed from January 2023 to May 2024.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURES: Genetic predictors of CAD, stroke, psoriasis, and 9 other IMIDs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary outcomes were the associations of genetic predictors of CAD and stroke with the risk of psoriasis and 9 other IMIDs, determined using inverse-variance weighted (IVW) MR estimates.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: This study included 181 249 cases and 1 165 690 controls with CAD, 110 182 cases and 1 503 898 controls with stroke, 36 466 cases and 458 078 controls with psoriasis, for a total of approximately 3 400 000 individuals, and 9 other IMIDs. In contrast to previous assumptions, genetic predictors of psoriasis were found to have no association with CAD or stroke. In the reverse direction, genetic predictors of both CAD (MR estimate IVW odds ratio [OR], 1.07; 95% CI, 1.04-1.10; P = .003) and stroke (IVW OR, 1.22; 95% CI, 1.05-1.41; P = .01) were found to have risk-increasing associations with psoriasis. Adjusting for stroke rendered the associations of genetically predicted CAD with psoriasis risk nonsignificant (and vice versa), suggesting that a shared effect underlying genetic risk for CAD and stroke associates with increased psoriasis risk. No risk-increasing associations were observed for genetic predictors of cardiovascular disease with other common IMIDs, including rheumatoid arthritis and inflammatory bowel disease.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Findings of this mendelian randomization study indicate that genetic predictors of cardiovascular disease were associated with increased psoriasis risk with no reciprocal effect or association with other IMIDs. Elucidating mechanisms underpinning this association could lead to novel therapeutic approaches in both diseases.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39292496/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240919001300&v=2.18.0.post9+e462414">39292496</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2859>10.1001/jamacardio.2024.2859</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39292496</guid>
<pubDate>Wed, 18 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Ravi Ramessur</dc:creator>
<dc:creator>Jake Saklatvala</dc:creator>
<dc:creator>Ashley Budu-Aggrey</dc:creator>
<dc:creator>Marek Ostaszewski</dc:creator>
<dc:creator>Lena Möbus</dc:creator>
<dc:creator>Dario Greco</dc:creator>
<dc:creator>Matladi Ndlovu</dc:creator>
<dc:creator>Satveer K Mahil</dc:creator>
<dc:creator>Jonathan N Barker</dc:creator>
<dc:creator>Sara Brown</dc:creator>
<dc:creator>Lavinia Paternoster</dc:creator>
<dc:creator>Nick Dand</dc:creator>
<dc:creator>Michael A Simpson</dc:creator>
<dc:creator>Catherine H Smith</dc:creator>
<dc:date>2024-09-18</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Exploring the Link Between Genetic Predictors of Cardiovascular Disease and Psoriasis</dc:title>
<dc:identifier>pmid:39292496</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2859</dc:identifier>
</item>
<item>
<title>Psoriasis and Atherosclerotic CV Disease-Risk Factor or Risk Marker?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39292493/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240919001300&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Sep 18. doi: 10.1001/jamacardio.2024.2868. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39292493/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240919001300&v=2.18.0.post9+e462414">39292493</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2868>10.1001/jamacardio.2024.2868</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39292493</guid>
<pubDate>Wed, 18 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Michael S Garshick</dc:creator>
<dc:creator>Brittany N Weber</dc:creator>
<dc:creator>Joel M Gelfand</dc:creator>
<dc:date>2024-09-18</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Psoriasis and Atherosclerotic CV Disease-Risk Factor or Risk Marker?</dc:title>
<dc:identifier>pmid:39292493</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2868</dc:identifier>
</item>
<item>
<title>Importance of Prolonged QRS Duration in Detecting Complete Conduction Block-Reply</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39292492/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240919001300&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Sep 18. doi: 10.1001/jamacardio.2024.2966. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39292492/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240919001300&v=2.18.0.post9+e462414">39292492</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2966>10.1001/jamacardio.2024.2966</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39292492</guid>
<pubDate>Wed, 18 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Jeremy S Treger</dc:creator>
<dc:creator>Gaurav A Upadhyay</dc:creator>
<dc:date>2024-09-18</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Importance of Prolonged QRS Duration in Detecting Complete Conduction Block-Reply</dc:title>
<dc:identifier>pmid:39292492</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2966</dc:identifier>
</item>
<item>
<title>Tailoring Risk Prediction Models to Local Populations</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39292486/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240919001300&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: The interpretable ML approach presented in this article enhanced the accuracy of the AHA-PREVENT model when applied to a local population while still preserving the risk associations found by the original model. This method has the potential to recalibrate other established risk tools and is implementable in electronic health record systems for improved cardiovascular risk assessment.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Sep 18. doi: 10.1001/jamacardio.2024.2912. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Risk estimation is an integral part of cardiovascular care. Local recalibration of guideline-recommended models could address the limitations of existing tools.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To provide a machine learning (ML) approach to augment the performance of the American Heart Association's Predicting Risk of Cardiovascular Disease Events (AHA-PREVENT) equations when applied to a local population while preserving clinical interpretability.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This cohort study used a New England-based electronic health record cohort of patients without prior atherosclerotic cardiovascular disease (ASCVD) who had the data necessary to calculate the AHA-PREVENT 10-year risk of developing ASCVD in the event period (2007-2016). Patients with prior ASCVD events, death prior to 2007, or age 79 years or older in 2007 were subsequently excluded. The final study population of 95 326 patients was split into 3 nonoverlapping subsets for training, testing, and validation. The AHA-PREVENT model was adapted to this local population using the open-source ML model (MLM) Extreme Gradient Boosting model (XGBoost) with minimal predictor variables, including age, sex, and AHA-PREVENT. The MLM was monotonically constrained to preserve known associations between risk factors and ASCVD risk. Along with sex, race and ethnicity data from the electronic health record were collected to validate the performance of ASCVD risk prediction in subgroups. Data were analyzed from August 2021 to February 2024.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Consistent with the AHA-PREVENT model, ASCVD events were defined as the first occurrence of either nonfatal myocardial infarction, coronary artery disease, ischemic stroke, or cardiovascular death. Cardiovascular death was coded via government registries. Discrimination, calibration, and risk reclassification were assessed using the Harrell C index, a modified Hosmer-Lemeshow goodness-of-fit test and calibration curves, and reclassification tables, respectively.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In the test set of 38 137 patients (mean [SD] age, 64.8 [6.9] years, 22 708 [59.5]% women and 15 429 [40.5%] men; 935 [2.5%] Asian, 2153 [5.6%] Black, 1414 [3.7%] Hispanic, 31 400 [82.3%] White, and 2235 [5.9%] other, including American Indian, multiple races, unspecified, and unrecorded, consolidated owing to small numbers), MLM-PREVENT had improved calibration (modified Hosmer-Lemeshow P >; .05) compared to the AHA-PREVENT model across risk categories in the overall cohort (χ23 = 2.2; P = .53 vs χ23 >; 16.3; P &lt; .001) and sex subgroups (men: χ23 = 2.1; P = .55 vs χ23 >; 16.3; P &lt; .001; women: χ23 = 6.5; P = .09 vs. χ23 >; 16.3; P &lt; .001), while also surpassing a traditional recalibration approach. MLM-PREVENT maintained or improved AHA-PREVENT's calibration in Asian, Black, and White individuals. Both MLM-PREVENT and AHA-PREVENT performed equally well in discriminating risk (approximate ΔC index, ±0.01). Using a clinically significant 7.5% risk threshold, MLM-PREVENT reclassified a total of 11.5% of patients. We visualize the recalibration through MLM-PREVENT ASCVD risk charts that highlight preserved risk associations of the original AHA-PREVENT model.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: The interpretable ML approach presented in this article enhanced the accuracy of the AHA-PREVENT model when applied to a local population while still preserving the risk associations found by the original model. This method has the potential to recalibrate other established risk tools and is implementable in electronic health record systems for improved cardiovascular risk assessment.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39292486/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240919001300&v=2.18.0.post9+e462414">39292486</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2912>10.1001/jamacardio.2024.2912</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39292486</guid>
<pubDate>Wed, 18 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Aniket N Zinzuwadia</dc:creator>
<dc:creator>Olga Mineeva</dc:creator>
<dc:creator>Chunying Li</dc:creator>
<dc:creator>Zareen Farukhi</dc:creator>
<dc:creator>Franco Giulianini</dc:creator>
<dc:creator>Brian Cade</dc:creator>
<dc:creator>Lin Chen</dc:creator>
<dc:creator>Elizabeth Karlson</dc:creator>
<dc:creator>Nina Paynter</dc:creator>
<dc:creator>Samia Mora</dc:creator>
<dc:creator>Olga Demler</dc:creator>
<dc:date>2024-09-18</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Tailoring Risk Prediction Models to Local Populations</dc:title>
<dc:identifier>pmid:39292486</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2912</dc:identifier>
</item>
<item>
<title>Preventing Site-Specific Calpain Proteolysis of Junctophilin-2 Protects Against Stress-Induced Excitation-Contraction Uncoupling and Heart Failure Development</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39291390/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240919001300&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The data presented here demonstrate that preserving JP2-dependent E-C coupling by prohibiting the site-specific calpain cleavage of JP2 offers multifaceted beneficial effects, conferring cardiac protection against stress-induced proteolysis, hypertrophy, and HF. Our data also indicate that specifically targeting the primary calpain cleavage site of JP2 by gene therapy approaches holds great therapeutic potential as a novel precision medicine for treating HF.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 18. doi: 10.1161/CIRCULATIONAHA.124.069329. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Excitation-contraction (E-C) coupling processes become disrupted in heart failure (HF), resulting in abnormal Ca<sup>2+</sup> homeostasis, maladaptive structural and transcriptional remodeling, and cardiac dysfunction. Junctophilin-2 (JP2) is an essential component of the E-C coupling apparatus but becomes site-specifically cleaved by calpain, leading to disruption of E-C coupling, plasmalemmal transverse tubule degeneration, abnormal Ca<sup>2+</sup> homeostasis, and HF. However, it is not clear whether preventing site-specific calpain cleavage of JP2 is sufficient to protect the heart against stress-induced pathological cardiac remodeling in vivo.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Calpain-resistant JP2 knock-in mice (JP2<sup>CR</sup>) were generated by deleting the primary JP2 calpain cleavage site. Stress-dependent JP2 cleavage was assessed through in vitro cleavage assays and in isolated cardiomyocytes treated with 1 μmol/L isoproterenol by immunofluorescence. Cardiac outcomes were assessed in wild-type and JP2<sup>CR</sup> mice 5 weeks after transverse aortic constriction compared with sham surgery using echocardiography, histology, and RNA-sequencing methods. E-C coupling efficiency was measured by in situ confocal microscopy. E-C coupling proteins were evaluated by calpain assays and Western blotting. The effectiveness of adeno-associated virus gene therapy with JP2<sup>CR</sup>, JP2, or green fluorescent protein to slow HF progression was evaluated in mice with established cardiac dysfunction.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: JP2 proteolysis by calpain and in response to transverse aortic constriction and isoproterenol was blocked in JP2<sup>CR</sup> cardiomyocytes. JP2<sup>CR</sup> hearts are more resistant to pressure-overload stress, having significantly improved Ca<sup>2+</sup> homeostasis and transverse tubule organization with significantly attenuated cardiac dysfunction, hypertrophy, lung edema, fibrosis, and gene expression changes relative to wild-type mice. JP2<sup>CR</sup> preserves the integrity of calpain-sensitive E-C coupling-related proteins, including ryanodine receptor 2, Ca<sub>V</sub>1.2, and sarcoplasmic reticulum calcium ATPase 2a, by attenuating transverse aortic constriction-induced increases in calpain activity. Furthermore, JP2<sup>CR</sup> gene therapy after the onset of cardiac dysfunction was found to be effective at slowing the progression of HF and superior to wild-type JP2.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The data presented here demonstrate that preserving JP2-dependent E-C coupling by prohibiting the site-specific calpain cleavage of JP2 offers multifaceted beneficial effects, conferring cardiac protection against stress-induced proteolysis, hypertrophy, and HF. Our data also indicate that specifically targeting the primary calpain cleavage site of JP2 by gene therapy approaches holds great therapeutic potential as a novel precision medicine for treating HF.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39291390/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240919001300&v=2.18.0.post9+e462414">39291390</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069329>10.1161/CIRCULATIONAHA.124.069329</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39291390</guid>
<pubDate>Wed, 18 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Jinxi Wang</dc:creator>
<dc:creator>Biyi Chen</dc:creator>
<dc:creator>Qian Shi</dc:creator>
<dc:creator>Grace Ciampa</dc:creator>
<dc:creator>Weiyang Zhao</dc:creator>
<dc:creator>Guangqin Zhang</dc:creator>
<dc:creator>Robert M Weiss</dc:creator>
<dc:creator>Tianqing Peng</dc:creator>
<dc:creator>Duane D Hall</dc:creator>
<dc:creator>Long-Sheng Song</dc:creator>
<dc:date>2024-09-18</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Preventing Site-Specific Calpain Proteolysis of Junctophilin-2 Protects Against Stress-Induced Excitation-Contraction Uncoupling and Heart Failure Development</dc:title>
<dc:identifier>pmid:39291390</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069329</dc:identifier>
</item>
<item>
<title>Successful management of cardiac hydatidosis complicated by rupture and embolism</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39291367/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240919001300&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 18:ehae605. doi: 10.1093/eurheartj/ehae605. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39291367/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240919001300&v=2.18.0.post9+e462414">39291367</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae605>10.1093/eurheartj/ehae605</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39291367</guid>
<pubDate>Wed, 18 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Daniel Barnés-Navarro</dc:creator>
<dc:creator>Gerard Martí-Aguasca</dc:creator>
<dc:creator>Aitor Uribarri</dc:creator>
<dc:date>2024-09-18</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Successful management of cardiac hydatidosis complicated by rupture and embolism</dc:title>
<dc:identifier>pmid:39291367</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae605</dc:identifier>
</item>
<item>
<title>The gut microbiota in thrombosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39289543/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240919001300&amp;v=2.18.0.post9+e462414
      <description>The gut microbiota has emerged as an environmental risk factor that affects thrombotic phenotypes in several cardiovascular diseases. Evidence includes the identification of marker species by sequencing studies of the gut microbiomes of patients with thrombotic disease, the influence of antithrombotic therapies on gut microbial diversity, and preclinical studies in mouse models of thrombosis that have demonstrated the functional effects of the gut microbiota on vascular inflammatory phenotypes...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Sep 17. doi: 10.1038/s41569-024-01070-6. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The gut microbiota has emerged as an environmental risk factor that affects thrombotic phenotypes in several cardiovascular diseases. Evidence includes the identification of marker species by sequencing studies of the gut microbiomes of patients with thrombotic disease, the influence of antithrombotic therapies on gut microbial diversity, and preclinical studies in mouse models of thrombosis that have demonstrated the functional effects of the gut microbiota on vascular inflammatory phenotypes and thrombus formation. In addition to impaired gut barrier function promoting low-grade inflammation, gut microbiota-derived metabolites have been shown to act on vascular cell types and promote thrombus formation. Therefore, these meta-organismal pathways that link the metabolic capacities of gut microorganisms with host immune functions have emerged as potential diagnostic markers and novel drug targets. In this Review, we discuss the link between the gut microbiota, its metabolites and thromboembolic diseases.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39289543/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240919001300&v=2.18.0.post9+e462414">39289543</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01070-6>10.1038/s41569-024-01070-6</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39289543</guid>
<pubDate>Tue, 17 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>My Phung Khuu</dc:creator>
<dc:creator>Nadja Paeslack</dc:creator>
<dc:creator>Olga Dremova</dc:creator>
<dc:creator>Corinne Benakis</dc:creator>
<dc:creator>Klytaimnistra Kiouptsi</dc:creator>
<dc:creator>Christoph Reinhardt</dc:creator>
<dc:date>2024-09-17</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>The gut microbiota in thrombosis</dc:title>
<dc:identifier>pmid:39289543</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01070-6</dc:identifier>
</item>
<item>
<title>Combined measure of inflammation, cholesterol and lipoprotein(a) predicts 30-year cardiovascular risk in women</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39289542/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240919001300&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Sep 17. doi: 10.1038/s41569-024-01082-2. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39289542/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240919001300&v=2.18.0.post9+e462414">39289542</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01082-2>10.1038/s41569-024-01082-2</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39289542</guid>
<pubDate>Tue, 17 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Karina Huynh</dc:creator>
<dc:date>2024-09-17</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Combined measure of inflammation, cholesterol and lipoprotein(a) predicts 30-year cardiovascular risk in women</dc:title>
<dc:identifier>pmid:39289542</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01082-2</dc:identifier>
</item>
<item>
<title>Clonal haematopoiesis: an emerging causal risk factor for atherosclerotic CVD</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39289541/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240919001300&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Sep 17. doi: 10.1038/s41569-024-01081-3. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39289541/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240919001300&v=2.18.0.post9+e462414">39289541</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01081-3>10.1038/s41569-024-01081-3</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39289541</guid>
<pubDate>Tue, 17 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Jennifer Harman</dc:creator>
<dc:date>2024-09-17</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Clonal haematopoiesis: an emerging causal risk factor for atherosclerotic CVD</dc:title>
<dc:identifier>pmid:39289541</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01081-3</dc:identifier>
</item>
<item>
<title>Reproductive options and genetic testing for patients with an inherited cardiac disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39289540/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240919001300&amp;v=2.18.0.post9+e462414
      <description>In the past decade, genetic testing for cardiac disease has become part of routine clinical care. A genetic diagnosis provides the possibility to clarify risk for relatives. For family planning, a genetic diagnosis provides reproductive options, including prenatal diagnosis and preimplantation genetic testing, that can prevent an affected parent from having a child with the genetic predisposition. Owing to the complex genetic architecture of cardiac diseases, characterized by incomplete disease...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Sep 17. doi: 10.1038/s41569-024-01073-3. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">In the past decade, genetic testing for cardiac disease has become part of routine clinical care. A genetic diagnosis provides the possibility to clarify risk for relatives. For family planning, a genetic diagnosis provides reproductive options, including prenatal diagnosis and preimplantation genetic testing, that can prevent an affected parent from having a child with the genetic predisposition. Owing to the complex genetic architecture of cardiac diseases, characterized by incomplete disease penetrance and the interplay between monogenic and polygenic variants, the risk reduction that can be achieved using reproductive genetic testing varies among individuals. Globally, disparities, including regulatory and financial barriers, in access to reproductive genetic tests exist. Although reproductive options are gaining a prominent position in the management of patients with inherited cardiac diseases, specific policies and guidance are lacking. Guidelines recommend that prenatal diagnosis and preimplantation genetic testing are options that should be discussed with families. Health-care professionals should, therefore, be aware of the possibilities and feel confident to discuss the benefits and challenges. In this Review, we provide an overview of the reproductive options in the context of inherited cardiac diseases, covering the genetic, technical, psychosocial and equity considerations, to prepare health-care professionals for discussions with their patients.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39289540/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240919001300&v=2.18.0.post9+e462414">39289540</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01073-3>10.1038/s41569-024-01073-3</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39289540</guid>
<pubDate>Tue, 17 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Job A J Verdonschot</dc:creator>
<dc:creator>Aimee D C Paulussen</dc:creator>
<dc:creator>Neal K Lakdawala</dc:creator>
<dc:creator>Christine E M de Die-Smulders</dc:creator>
<dc:creator>James S Ware</dc:creator>
<dc:creator>Jodie Ingles</dc:creator>
<dc:date>2024-09-17</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Reproductive options and genetic testing for patients with an inherited cardiac disease</dc:title>
<dc:identifier>pmid:39289540</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01073-3</dc:identifier>
</item>
<item>
<title>Interferon response at the border zone of the infarcted heart</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39289539/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240919001300&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Sep 17. doi: 10.1038/s41569-024-01078-y. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39289539/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240919001300&v=2.18.0.post9+e462414">39289539</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01078-y>10.1038/s41569-024-01078-y</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39289539</guid>
<pubDate>Tue, 17 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Karina Huynh</dc:creator>
<dc:date>2024-09-17</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Interferon response at the border zone of the infarcted heart</dc:title>
<dc:identifier>pmid:39289539</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01078-y</dc:identifier>
</item>
<item>
<title>Dynamic allostery drives autocrine and paracrine TGF-β signaling</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39288764/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240919001300&amp;v=2.18.0.post9+e462414
      <description>TGF-β, essential for development and immunity, is expressed as a latent complex (L-TGF-β) non-covalently associated with its prodomain and presented on immune cell surfaces by covalent association with GARP. Binding to integrin αvβ8 activates L-TGF-β1/GARP. The dogma is that mature TGF-β must physically dissociate from L-TGF-β1 for signaling to occur. Our previous studies discovered that αvβ8-mediated TGF-β autocrine signaling can occur without TGF-β1 release from its latent form. Here, we show...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Sep 12:S0092-8674(24)00965-6. doi: 10.1016/j.cell.2024.08.036. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TGF-β, essential for development and immunity, is expressed as a latent complex (L-TGF-β) non-covalently associated with its prodomain and presented on immune cell surfaces by covalent association with GARP. Binding to integrin αvβ8 activates L-TGF-β1/GARP. The dogma is that mature TGF-β must physically dissociate from L-TGF-β1 for signaling to occur. Our previous studies discovered that αvβ8-mediated TGF-β autocrine signaling can occur without TGF-β1 release from its latent form. Here, we show that mice engineered to express TGF-β1 that cannot release from L-TGF-β1 survive without early lethal tissue inflammation, unlike those with TGF-β1 deficiency. Combining cryogenic electron microscopy with cell-based assays, we reveal a dynamic allosteric mechanism of autocrine TGF-β1 signaling without release where αvβ8 binding redistributes the intrinsic flexibility of L-TGF-β1 to expose TGF-β1 to its receptors. Dynamic allostery explains the TGF-β3 latency/activation mechanism and why TGF-β3 functions distinctly from TGF-β1, suggesting that it broadly applies to other flexible cell surface receptor/ligand systems.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39288764/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240919001300&v=2.18.0.post9+e462414">39288764</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.08.036>10.1016/j.cell.2024.08.036</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39288764</guid>
<pubDate>Tue, 17 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Mingliang Jin</dc:creator>
<dc:creator>Robert I Seed</dc:creator>
<dc:creator>Guoqing Cai</dc:creator>
<dc:creator>Tiffany Shing</dc:creator>
<dc:creator>Li Wang</dc:creator>
<dc:creator>Saburo Ito</dc:creator>
<dc:creator>Anthony Cormier</dc:creator>
<dc:creator>Stephanie A Wankowicz</dc:creator>
<dc:creator>Jillian M Jespersen</dc:creator>
<dc:creator>Jody L Baron</dc:creator>
<dc:creator>Nicholas D Carey</dc:creator>
<dc:creator>Melody G Campbell</dc:creator>
<dc:creator>Zanlin Yu</dc:creator>
<dc:creator>Phu K Tang</dc:creator>
<dc:creator>Pilar Cossio</dc:creator>
<dc:creator>Weihua Wen</dc:creator>
<dc:creator>Jianlong Lou</dc:creator>
<dc:creator>James Marks</dc:creator>
<dc:creator>Stephen L Nishimura</dc:creator>
<dc:creator>Yifan Cheng</dc:creator>
<dc:date>2024-09-17</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Dynamic allostery drives autocrine and paracrine TGF-β signaling</dc:title>
<dc:identifier>pmid:39288764</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.08.036</dc:identifier>
</item>
<item>
<title>Multimodal imaging in Löffler's endocarditis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39288274/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240919001300&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 17:ehae620. doi: 10.1093/eurheartj/ehae620. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39288274/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240919001300&v=2.18.0.post9+e462414">39288274</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae620>10.1093/eurheartj/ehae620</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39288274</guid>
<pubDate>Tue, 17 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Kosuke Morita</dc:creator>
<dc:creator>Nobuhiro Tahara</dc:creator>
<dc:creator>Yoshihiro Fukumoto</dc:creator>
<dc:date>2024-09-17</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Multimodal imaging in Löffler's endocarditis</dc:title>
<dc:identifier>pmid:39288274</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae620</dc:identifier>
</item>
<item>
<title>Traditional Chinese medicine: cardiovascular drug development through a holistic framework</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39288272/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240919001300&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 17:ehae625. doi: 10.1093/eurheartj/ehae625. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39288272/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240919001300&v=2.18.0.post9+e462414">39288272</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae625>10.1093/eurheartj/ehae625</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39288272</guid>
<pubDate>Tue, 17 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Milton Packer</dc:creator>
<dc:date>2024-09-17</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Traditional Chinese medicine: cardiovascular drug development through a holistic framework</dc:title>
<dc:identifier>pmid:39288272</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae625</dc:identifier>
</item>
<item>
<title>Clinical features and outcomes in carriers of pathogenic desmoplakin variants</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39288222/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240919001300&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Patients with P/LP DSP variants experience high rates of sustained VA and HF hospitalizations. These patients demonstrate a distinct clinical phenotype (DSP cardiomyopathy), whose most prominent risk features associated with adverse clinical outcomes are the presence of prior non-sustained ventricular tachycardia or sustained VA, T-wave inversion in 3+ leads on electrocardiogram, LVEF ≤ 50%, and myocardial injury events.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 17:ehae571. doi: 10.1093/eurheartj/ehae571. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Pathogenic variants in the desmoplakin (DSP) gene are associated with the development of a distinct arrhythmogenic cardiomyopathy phenotype not fully captured by either dilated cardiomyopathy (DCM), non-dilated left ventricular cardiomyopathy (NDLVC), or arrhythmogenic right ventricular cardiomyopathy (ARVC). Prior studies have described baseline DSP cardiomyopathy genetic, inflammatory, and structural characteristics. However, cohort sizes have limited full clinical characterization and identification of clinical and demographic predictors of sustained ventricular arrhythmias (VAs), heart failure (HF) hospitalizations, and transplant/death. In particular, the relevance of acute myocarditis-like episodes for subsequent disease course is largely unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: All patients with pathogenic/likely pathogenic (P/LP) DSP variants in the worldwide DSP-ERADOS Network (26 academic institutions across nine countries) were included. The primary outcomes were the development of sustained VA and HF hospitalizations during follow-up. Fine-Gray regressions were used to test association between clinical and instrumental parameters and the development of outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Eight hundred patients [40.3 ± 17.5 years, 47.5% probands, left ventricular ejection fraction (LVEF) 49.5 ± 13.9%] were included. Over 3.7 [1.4-7.1] years, 139 (17.4%, 3.9%/year) and 72 (9.0%, 1.8%/year) patients experienced sustained VA and HF episodes, respectively. A total of 32.5% of individuals did not fulfil diagnostic criteria for ARVC, DCM, or NDLVC; their VA incidence was 0.5%/year. In multivariable regression, risk features associated with the development of VA were female sex [adjusted hazard ratio (aHR) 1.547; P = .025], prior non-sustained ventricular tachycardia (aHR 1.721; P = .009), prior sustained VA (aHR 1.923; P = .006), and LVEF ≤ 50% (aHR: 1.645; P = .032), while for HF, they were the presence of T-wave inversion in 3+ electrocardiogram leads (aHR 2.036, P = .007) and LVEF ≤ 50% (aHR 3.879; P &lt; .001). Additionally, 70 (8.8%) patients experienced a myocardial injury episode at presentation or during follow-up. These episodes were associated with an increased risk of VA and HF thereafter (HR 2.394; P &lt; .001, and HR 5.064, P &lt; .001, respectively).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Patients with P/LP DSP variants experience high rates of sustained VA and HF hospitalizations. These patients demonstrate a distinct clinical phenotype (DSP cardiomyopathy), whose most prominent risk features associated with adverse clinical outcomes are the presence of prior non-sustained ventricular tachycardia or sustained VA, T-wave inversion in 3+ leads on electrocardiogram, LVEF ≤ 50%, and myocardial injury events.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39288222/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240919001300&v=2.18.0.post9+e462414">39288222</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae571>10.1093/eurheartj/ehae571</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39288222</guid>
<pubDate>Tue, 17 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Alessio Gasperetti</dc:creator>
<dc:creator>Richard T Carrick</dc:creator>
<dc:creator>Alexandros Protonotarios</dc:creator>
<dc:creator>Brittney Murray</dc:creator>
<dc:creator>Mikael Laredo</dc:creator>
<dc:creator>Iris van der Schaaf</dc:creator>
<dc:creator>Ronald H Lekanne</dc:creator>
<dc:creator>Petros Syrris</dc:creator>
<dc:creator>Douglas Cannie</dc:creator>
<dc:creator>Crystal Tichnell</dc:creator>
<dc:creator>Chiara Cappelletto</dc:creator>
<dc:creator>Marta Gigli</dc:creator>
<dc:creator>Kristen Medo</dc:creator>
<dc:creator>Ardan M Saguner</dc:creator>
<dc:creator>Firat Duru</dc:creator>
<dc:creator>Nisha A Gilotra</dc:creator>
<dc:creator>Stefan Zimmerman</dc:creator>
<dc:creator>Robyn Hylind</dc:creator>
<dc:creator>Dominic J Abrams</dc:creator>
<dc:creator>Neal K Lakdawala</dc:creator>
<dc:creator>Julia Cadrin-Tourigny</dc:creator>
<dc:creator>Mattia Targetti</dc:creator>
<dc:creator>Iacopo Olivotto</dc:creator>
<dc:creator>Maddalena Graziosi</dc:creator>
<dc:creator>Moniek Cox</dc:creator>
<dc:creator>Elena Biagini</dc:creator>
<dc:creator>Philippe Charron</dc:creator>
<dc:creator>Michela Casella</dc:creator>
<dc:creator>Claudio Tondo</dc:creator>
<dc:creator>Momina Yazdani</dc:creator>
<dc:creator>James S Ware</dc:creator>
<dc:creator>Sanjay K Prasad</dc:creator>
<dc:creator>Leonardo Calò</dc:creator>
<dc:creator>Eric D Smith</dc:creator>
<dc:creator>Adam S Helms</dc:creator>
<dc:creator>Sophie Hespe</dc:creator>
<dc:creator>Jodie Ingles</dc:creator>
<dc:creator>Harikrishna Tandri</dc:creator>
<dc:creator>Flavie Ader</dc:creator>
<dc:creator>Giovanni Peretto</dc:creator>
<dc:creator>Stacey Peters</dc:creator>
<dc:creator>Ari Horton</dc:creator>
<dc:creator>Jess Yao</dc:creator>
<dc:creator>Sven Dittmann</dc:creator>
<dc:creator>Eric Schulze-Bahr</dc:creator>
<dc:creator>Maria Qureshi</dc:creator>
<dc:creator>Katelyn Young</dc:creator>
<dc:creator>Eric D Carruth</dc:creator>
<dc:creator>Chris Haggerty</dc:creator>
<dc:creator>Victoria N Parikh</dc:creator>
<dc:creator>Matthew Taylor</dc:creator>
<dc:creator>Luisa Mestroni</dc:creator>
<dc:creator>Arthur Wilde</dc:creator>
<dc:creator>Gianfranco Sinagra</dc:creator>
<dc:creator>Marco Merlo</dc:creator>
<dc:creator>Estelle Gandjbakhch</dc:creator>
<dc:creator>J Peter van Tintelen</dc:creator>
<dc:creator>Anneline S J M Te Riele</dc:creator>
<dc:creator>Perry M Elliott</dc:creator>
<dc:creator>Hugh Calkins</dc:creator>
<dc:creator>Cynthia A James</dc:creator>
<dc:date>2024-09-17</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Clinical features and outcomes in carriers of pathogenic desmoplakin variants</dc:title>
<dc:identifier>pmid:39288222</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae571</dc:identifier>
</item>
<item>
<title>Diet and risk of atrial fibrillation: a systematic review</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39288159/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240919001300&amp;v=2.18.0.post9+e462414
      <description>Atrial fibrillation (AF) is the most prevalent sustained cardiac arrhythmia. Comprehensive modification of established AF risk factors combined with dietary interventions and breaking deleterious habits has been shown to reduce AF burden and recurrence. Numerous AF risk factors, such as diabetes, obesity or hypertension can be partially related to dietary and lifestyle choices. Therefore, dietary interventions may have potential as a therapeutic approach in AF. Based on available data, current...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 17:ehae551. doi: 10.1093/eurheartj/ehae551. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Atrial fibrillation (AF) is the most prevalent sustained cardiac arrhythmia. Comprehensive modification of established AF risk factors combined with dietary interventions and breaking deleterious habits has been shown to reduce AF burden and recurrence. Numerous AF risk factors, such as diabetes, obesity or hypertension can be partially related to dietary and lifestyle choices. Therefore, dietary interventions may have potential as a therapeutic approach in AF. Based on available data, current guidelines recommend alcohol abstinence or reduction to decrease AF symptoms, burden, and progression, and do not indicate the need for caffeine abstention to prevent AF episodes (unless it is a trigger for AF symptoms). Uncertainty persists regarding harms or benefits of other dietary factors including chocolate, fish, salt, polyunsaturated and monounsaturated fatty acids, vitamins, and micronutrients. This article provides a systematic review of the association between AF and both dietary patterns and components. Additionally, it discusses potentially related mechanisms and introduces different strategies to assess patients' nutrition patterns, including mobile health solutions and diet indices. Finally, it highlights the gaps in knowledge requiring future investigation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39288159/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240919001300&v=2.18.0.post9+e462414">39288159</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae551>10.1093/eurheartj/ehae551</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39288159</guid>
<pubDate>Tue, 17 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Monika Gawałko</dc:creator>
<dc:creator>Melissa E Middeldorp</dc:creator>
<dc:creator>Arnela Saljic</dc:creator>
<dc:creator>John Penders</dc:creator>
<dc:creator>Thomas Jespersen</dc:creator>
<dc:creator>Christine M Albert</dc:creator>
<dc:creator>Gregory M Marcus</dc:creator>
<dc:creator>Christopher X Wong</dc:creator>
<dc:creator>Prashanthan Sanders</dc:creator>
<dc:creator>Dominik Linz</dc:creator>
<dc:date>2024-09-17</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Diet and risk of atrial fibrillation: a systematic review</dc:title>
<dc:identifier>pmid:39288159</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae551</dc:identifier>
</item>
<item>
<title>Correction to: Electrical storm treatment by percutaneous stellate ganglion block: the STAR study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39287435/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240919001300&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 17:ehae631. doi: 10.1093/eurheartj/ehae631. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39287435/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240919001300&v=2.18.0.post9+e462414">39287435</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae631>10.1093/eurheartj/ehae631</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39287435</guid>
<pubDate>Tue, 17 Sep 2024 06:00:00 -0400</pubDate>
<dc:date>2024-09-17</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Correction to: Electrical storm treatment by percutaneous stellate ganglion block: the STAR study</dc:title>
<dc:identifier>pmid:39287435</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae631</dc:identifier>
</item>
<item>
<title>Worldwide CTEPH Registry: Long-Term Outcomes With Pulmonary Endarterectomy, Balloon Pulmonary Angioplasty, and Medical Therapy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39286890/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240919001300&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: This second international CTEPH registry reveals important improvement in patient survival since the introduction of BPA and an approved drug for pulmonary hypertension. The type of anticoagulation regimen did not influence survival.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 17. doi: 10.1161/CIRCULATIONAHA.124.068610. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The European Chronic Thromboembolic Pulmonary Hypertension registry (CTEPH), conducted between 2007 and 2012, reported the major impact of pulmonary endarterectomy (PEA) on the long-term survival of patients with CTEPH. Since then, 2 additional treatments for inoperable CTEPH have become available: balloon pulmonary angioplasty (BPA), and an approved oral drug therapy with the guanylate cyclase stimulator riociguat. The current registry aimed to evaluate the effect of these new therapeutic approaches in a worldwide context.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Participation in this international global registry included 34 centers in 20 countries. Between February 2015 and September 2016, 1009 newly diagnosed, consecutive patients were included and followed until September 2019.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Overall, 605 patients (60%) underwent PEA and 185 (18%) underwent BPA; 76% of the 219 remaining patients not receiving mechanical intervention (ie, neither PEA nor BPA) were treated with pulmonary hypertension drugs. Oof patients undergoing PEA and BPA, 38% and 78% also received drugs for pulmonary hypertension, respectively. Median age at diagnosis was higher in the BPA and No PEA/BPA groups than in the PEA group: 66 and 69, respectively, versus 60 years. Pulmonary vascular resistance (PVR) was similar in all groups, with an average of 643 dynes/(s·cm<sup>-5</sup>). During an observation period (>;3 years; ≤5.6 years), death was reported in 7%, 11%, and 27% of patients treated by PEA and BPA, and those receiving no mechanical intervention (<i>P</i>&lt;0.001). In Kaplan-Meier analysis, 3-year survival was 94%, 92%, and 71% in the 3 groups, respectively. PEA 3-year survival improved by 5% from that observed between 2007 and 2012. There was no survival difference in patients receiving vitamin K antagonists and non-vitamin K oral anticoagulants (<i>P</i>=0.756). In Cox regression, reduced mortality was associated with: PEA and BPA in the global cohort; history of venous thromboembolism and lower PVR in the PEA group; lower right atrial pressure in the BPA group; and use of pulmonary hypertension drugs, oxygen therapy, and lower right atrial pressure, as well as functional class in the group receiving no mechanical intervention.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This second international CTEPH registry reveals important improvement in patient survival since the introduction of BPA and an approved drug for pulmonary hypertension. The type of anticoagulation regimen did not influence survival.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL https://clinicaltrials.gov; Unique identifier: NCT02656238.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39286890/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240919001300&v=2.18.0.post9+e462414">39286890</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.068610>10.1161/CIRCULATIONAHA.124.068610</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39286890</guid>
<pubDate>Tue, 17 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Marion Delcroix</dc:creator>
<dc:creator>Joanna Pepke-Zaba</dc:creator>
<dc:creator>Andrea M D'Armini</dc:creator>
<dc:creator>Elie Fadel</dc:creator>
<dc:creator>Stefan Guth</dc:creator>
<dc:creator>Stephen P Hoole</dc:creator>
<dc:creator>David P Jenkins</dc:creator>
<dc:creator>David G Kiely</dc:creator>
<dc:creator>Nick H Kim</dc:creator>
<dc:creator>Michael M Madani</dc:creator>
<dc:creator>Hiromi Matsubara</dc:creator>
<dc:creator>Kazuhiko Nakayama</dc:creator>
<dc:creator>Aiko Ogawa</dc:creator>
<dc:creator>Jaquelina S Ota-Arakaki</dc:creator>
<dc:creator>Rozenn Quarck</dc:creator>
<dc:creator>Roela Sadushi-Kolici</dc:creator>
<dc:creator>Gérald Simonneau</dc:creator>
<dc:creator>Christoph B Wiedenroth</dc:creator>
<dc:creator>Bedrettin Yildizeli</dc:creator>
<dc:creator>Eckhard Mayer</dc:creator>
<dc:creator>Irene M Lang</dc:creator>
<dc:date>2024-09-17</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Worldwide CTEPH Registry: Long-Term Outcomes With Pulmonary Endarterectomy, Balloon Pulmonary Angioplasty, and Medical Therapy</dc:title>
<dc:identifier>pmid:39286890</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.068610</dc:identifier>
</item>
<item>
<title>Differential roles of eosinophils in cardiovascular disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39285242/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240919001300&amp;v=2.18.0.post9+e462414
      <description>Eosinophils are essential innate immune cells in allergic responses. Accumulating evidence indicates that eosinophils also participate in the pathogenesis of cardiovascular diseases (CVDs). In clinical studies, high blood eosinophil counts and eosinophil cationic protein levels have been associated with an increased risk of CVD, including myocardial infarction (MI), cardiac hypertrophy, atrial fibrillation, abdominal aortic aneurysm (AAA) and atherosclerosis. However, low blood eosinophil counts...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Sep 16. doi: 10.1038/s41569-024-01071-5. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Eosinophils are essential innate immune cells in allergic responses. Accumulating evidence indicates that eosinophils also participate in the pathogenesis of cardiovascular diseases (CVDs). In clinical studies, high blood eosinophil counts and eosinophil cationic protein levels have been associated with an increased risk of CVD, including myocardial infarction (MI), cardiac hypertrophy, atrial fibrillation, abdominal aortic aneurysm (AAA) and atherosclerosis. However, low blood eosinophil counts have also been reported to be a risk factor for MI, heart failure, aortic dissection, AAA, deep vein thrombosis, pulmonary embolism and ischaemic stroke. Although these conflicting clinical observations remain unexplained, CVD status, timing of eosinophil data collection, and tissue eosinophil phenotypic and functional heterogeneities might account for these discrepancies. Preclinical studies suggest that eosinophils have protective actions in MI, cardiac hypertrophy, heart failure and AAA. By contrast, cationic proteins and platelet-activating factor from eosinophils have been shown to promote vascular smooth muscle cell proliferation, vascular calcification, thrombomodulin inactivation and platelet activation and aggregation, thereby exacerbating atherosclerosis, atrial fibrillation, thrombosis and associated complications. Therefore, eosinophils seem to promote calcification and thrombosis in chronic CVD but are protective in acute cardiovascular settings. In this Review, we summarize the available clinical and preclinical data on the different roles of eosinophils in CVD.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39285242/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240919001300&v=2.18.0.post9+e462414">39285242</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01071-5>10.1038/s41569-024-01071-5</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39285242</guid>
<pubDate>Mon, 16 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Junyan Xu</dc:creator>
<dc:creator>Junli Guo</dc:creator>
<dc:creator>Tianxiao Liu</dc:creator>
<dc:creator>Chongzhe Yang</dc:creator>
<dc:creator>Zhaojie Meng</dc:creator>
<dc:creator>Peter Libby</dc:creator>
<dc:creator>Jinying Zhang</dc:creator>
<dc:creator>Guo-Ping Shi</dc:creator>
<dc:date>2024-09-16</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Differential roles of eosinophils in cardiovascular disease</dc:title>
<dc:identifier>pmid:39285242</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01071-5</dc:identifier>
</item>
<item>
<title>Correction to: 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39283938/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240919001300&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 17;150(12):e267. doi: 10.1161/CIR.0000000000001284. Epub 2024 Sep 16.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39283938/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240919001300&v=2.18.0.post9+e462414">39283938</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001284>10.1161/CIR.0000000000001284</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39283938</guid>
<pubDate>Mon, 16 Sep 2024 06:00:00 -0400</pubDate>
<dc:date>2024-09-16</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines</dc:title>
<dc:identifier>pmid:39283938</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001284</dc:identifier>
</item>





























</channel>
</rss>